|2.48|| +0.17 / +7.36%|
GenVec, Inc. is a clinical-stage biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. It is working with other companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. The company's development programs address therapeutic areas such as hearing loss, balance disorders and cancer; as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever and malaria. GenVec was founded in December 1992 and is headquartered in Gaithersburg, MD.
|Douglas J. Swirsky||President, CEO, Secretary & Director|
|James Vincent Lambert||CFO, Treasurer, CAO & Controller|
|Douglas E. Brough||Chief Scientific Officer|
|Bryan T. Butman||Senior Vice President-Development|
|Rena Cohen||Head-Investor Relations|